​

Trevi Therapeutics Ownership | Who Owns Trevi Therapeutics?

OverviewForecastFinancialsChartTranscripts

Trevi Therapeutics Ownership Summary

Trevi Therapeutics is owned by 12.52% institutional investors, 0.63% insiders, and 86.85% retail investors. Nea management company is the largest institutional shareholder, holding 9.09% of TRVI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.83% of its assets in Trevi Therapeutics shares.

TRVI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTrevi Therapeutics12.52%0.63%86.85%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Nea management company13.22M9.09%$157.74M
Blackrock funding, inc. /de10.24M7.04%$122.17M
Frazier life sciences management9.94M6.83%$118.58M
Fmr8.04M5.52%$95.89M
Vanguard group6.43M4.43%$80.56M
Wellington management group llp5.19M3.57%$61.91M
Vivo capital5.09M3.50%$60.78M
Blackrock3.14M3.15%$9.34M
Marshall wace, llp3.97M2.73%$47.31M
Rubric capital management lp3.71M2.55%$44.29M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Nea management company13.22M8.97%$157.74M
Acorn capital advisors2.14M7.27%$25.59M
Pivotal bioventure partners investment advisor1.55M6.63%$18.54M
Artia global partners lp2.01M5.29%$24.02M
Vivo capital5.09M5.07%$60.78M
Frazier life sciences management9.94M3.05%$118.58M
Bioimpact capital3.30M3.04%$39.35M
Superstring capital management lp251.57K2.14%$3.00M
Octagon capital advisors lp1.49M1.96%$17.72M
Propel bio management223.80K1.67%$2.65M

Top Buyers

HolderShares% AssetsChange
Vestal point capital, lp2.17M0.72%2.17M
Wellington management group llp5.19M0.01%1.79M
Fmr8.04M0.01%1.54M
Citadel advisors1.20M0.00%1.05M
Frontier capital management1.99M0.24%885.82K

Top Sellers

HolderShares% AssetsChange
Armistice capital---2.99M
Octagon capital advisors lp1.49M1.96%-1.33M
Point72 asset management---1.00M
Orbimed advisors2.45M0.58%-736.30K
Ally bridge group (ny)---686.22K

New Positions

HolderShares% AssetsChangeValue
Vestal point capital, lp2.17M0.72%2.17M$25.85M
Candriam s.c.a.773.62K0.05%773.62K$9.23M
Vanguard fiduciary trust714.63K0.00%714.63K$8.53M
Ensign peak advisors464.75K0.01%464.75K$5.54M
Gmt capital317.70K0.17%317.70K$3.79M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-6.00
Clearstead advisors-39.00
Coldstream capital management-78.00
Capital performance advisors llp-134.00
Srs capital advisors-206.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202680-58.12%18,222,593-86.02%120.16%44-58.49%23-54.00%
Dec 31, 2025113-34.30%64,895,069-49.82%440.45%68-32.67%27-37.21%
Sep 30, 20251699.03%127,167,79618.08%971.43%99-1.98%4334.38%
Jun 30, 202516214.08%114,632,70430.70%871.58%1046.12%336.45%
Mar 31, 202514224.56%88,122,13510.86%741.21%9836.11%3233.33%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv4.02M2.83%321.25K
Eventide Healthcare & Life Sciences I2.62M2.04%1.24M
Vanguard US Total Market Shares ETF1.78M1.84%-
Fidelity Select Biotechnology2.38M1.68%90.00K
iShares Russell 2000 ETF2.26M1.59%19.04K
MEDICAL BioHealth EUR Acc1.39M0.98%-1.42K
Vanguard Institutional Extnd Mkt Idx Tr1.31M0.92%146.30K
Fidelity Small Cap Growth1.29M0.91%-
AB Small Cap Growth A1.25M0.88%-34.89K
Pictet-Biotech P USD1.11M0.78%4.36K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 25, 2025SCIASCIA THOMAS Chief Scientific OfficerSell$17.36K
Mar 21, 2025GOOD JENNIFER L President & CEOSell$34.62K
Mar 10, 2025Simon Farrell Chief Commercial OfficerSell$31.10K
Mar 10, 2025Simon Farrell Chief Commercial OfficerSell$517.78K
Sep 06, 2024GOOD JENNIFER L President & CEOSell$12.78K

Insider Transactions Trends

DateBuySell
2026 Q2--
2026 Q1--
2025 Q4--
2025 Q2--
2025 Q1-4

TRVI Ownership FAQ

Who Owns Trevi Therapeutics?

Trevi Therapeutics shareholders are primarily institutional investors at 12.52%, followed by 0.63% insiders and 86.85% retail investors. The average institutional ownership in Trevi Therapeutics's industry, Biotech Stocks , is 35.75%, which Trevi Therapeutics falls below.

Who owns the most shares of Trevi Therapeutics?

Trevi Therapeutics’s largest shareholders are Nea management company (13.22M shares, 9.09%), Blackrock funding, inc. /de (10.24M shares, 7.04%), and Frazier life sciences management (9.94M shares, 6.83%). Together, they hold 22.96% of Trevi Therapeutics’s total shares outstanding.

Does Blackrock own Trevi Therapeutics?

Yes, BlackRock owns 3.15% of Trevi Therapeutics, totaling 3.14M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 9.34M$. In the last quarter, BlackRock increased its holdings by 759.41K shares, a 31.97% change.

Who is Trevi Therapeutics’s biggest shareholder by percentage of total assets invested?

Nea management company is Trevi Therapeutics’s biggest shareholder by percentage of total assets invested, with 8.97% of its assets in 13.22M Trevi Therapeutics shares, valued at 157.74M$.

Who is the top mutual fund holder of Trevi Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Trevi Therapeutics shares, with 2.83% of its total shares outstanding invested in 4.02M Trevi Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools